| Formulary Chapter 1: Gastro-intestinal system - Full Chapter
|
| 01.09 |
Drugs affecting intestinal secretions |
|
|
Colesevelam (Cholestagel®)
|
Formulary
|
Supported by a RICaD (in development)
|
|
|
Colestyramine
(Powder)
|
Formulary
|
Supported by a RICaD (In development)
|
|
|
Obeticholic acid (Ocaliva®)
(Tablets)
|
Formulary
|
NHSE commissioned
In line with NICE
|
 NICE TA443: Obeticholic acid for treating primary biliary cholangitis
|
Octreotide
(Injection)
|
Formulary
|
|
|
|
Rifaximin
(Tablets)
|
Formulary
|
In line with NICE, supported by RICaD (In development)
|
NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
|
Terlipressin (Glypressin®)
|
Formulary
|
|
|
|
Ursodeoxycholic acid
(Capsules. Tablets)
|
Formulary
|
For specialist initiation only
|
|
|
Vasopressin (Pitressin®)
|
Formulary
|
|
|
|
| 01.09.01 |
Drugs affecting biliary composition and flow |
|
|
| 01.09.01 |
Other prepatations for biliary disorders |
|
|
| 01.09.02 |
Bile acid sequestrants |
|
|
| 01.09.03 |
Aprotinin |
|
|
| 01.09.04 |
Pancreatin |
|
|
Pancreatin (Creon 10,000 ®, Creon 25,000 ®)
(Capsules)
|
First Choice
|
For specialist initiation
Counsel patient on need for adequate hydration
Prescribe by Brand only
Use brand and strength recommended by specialist
|
|
|
Pancreatin (Pancrex V®)
(Powder)
|
Second Choice
|
For Specialist initiation
Counsel patient on need for adequate hydration
Prescribe by Brand only
Use brand and strength recommended by specialist
|
|
|
| .... |
| Non Formulary Items |
Borneol with camphene, cineole, menthol, menthone and pinene
|
Non Formulary
|
|
|
|
Chenodeoxycholic acid
|
Non Formulary
|
|
|
|
Cholic acid
|
Non Formulary
|
|
|
|
Pancreatin (Nutrizym 10®)
|
Non Formulary
|
|
|
|
Pancreatin (Pancrease HL®)
|
Non Formulary
|
|
|
|
Rowachol
|
Non Formulary
|
|
|
|
Rowachol®
|
Non Formulary
|
|
|
|
| |
Key |
 |
Restricted Drug |
 |
Unlicensed |
|
|
Link to adult BNF
|
|
|
Link to children's BNF
|
|
|
Link to SPCs
|
|
Cytotoxic Drug |
|
Controlled Drug |
|
|
High Cost Medicine |
|
Cancer Drugs Fund |
|
NHS England |
|
Homecare |
|
ICB |
|
Low carbon footprint |
|
Medium carbon footprint |
|
High carbon footprint |
|
| Status |
Description |
|
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications |
|
Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry. |
|
Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry. |
|
Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a specialist. |
|
Medicines for initiation and maintenance prescribing by Specialists (hospital or GPs with Special Interest) only |
|
Positive NICE TA and /or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information. |
|
Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use. |
|
Check Notes as varies across the area |
|
|
|
